Document is current
Any future updates will be listed below
-
Authors
Ota, Kazuki
Shinzato, Hotaka
Otsuka, Naoaki
Zamami, Yu
Kurihara, Kazuhiro
Futenma, Kunihiro
Kondo, Tsuyoshi
Takaesu, Yoshikazu
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (JP22K15763, JP17K10311, JP24K10682)
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 27 February 2025
First Online: 7 April 2025
Declarations
:
: Kazuki Ota, Naoaki Otsuka, and Kazuhiro Kurihara had no conflicts of interest to declare that may affect the publication of this manuscript. Yu Zamami received an honorarium from Takeda Pharmaceutical, Sumitomo Pharma, Otsuka Pharmaceutical, Meiji Seika, and Viatris. Hotaka Shinzato received an honorarium from Sumitomo Pharma, Kowa, and Lundbeck. Kunihiro Futenma received an honorarium from Esai and MSD. Tsuyoshi Kondo received an honorarium from Takeda Pharmaceutical, Sumitomo Pharma, Otsuka Pharmaceutical, Meiji Seika Pharma, Kyowa Pharmaceutical, Eisai, MSD, and Yoshitomi Pharmaceutical. Yoshikazu Takaesu received an honorarium from Eisai, Sumitomo Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Shionogi, MSD, and Otsuka Pharmaceutical.
: The Ethics Committee of the National Hospital Organization Ryukyu Hospital approved the study protocol (Approval Number 29−21).
: All participants provided written informed consent before their involvement in the study.
